Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical TrialYan Zhao, Jing Li, Bin Yang et al.|BioDrugs|2024Cited by 16